scPharmaceuticals Inc.
SCPHDelisted Oct 7, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001604950
scPharmaceuticals Inc. was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 7, 2025; 110 institutions reported holding it in 13F filings for Q3 2025, worth $232.3M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 110
- Q3 2025, +12 vs. previous quarter
- 13F value
- $232.3M
- Reported value at the end of Q3 2025
- Superinvestors holding
- 0
- At the end of Q3 2025
Superinvestors holding SCPH, Q3 2025
No superinvestor reported holding SCPH at the end of Q3 2025.
Latest insider trades
Open-market purchases and sales by scPharmaceuticals Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 15, 2024 (view filing)4:51 PM ET | Aug 13 | 2 days | OrbiMed Advisors LLC and 2 others10% Owner | PPurchase | +500.0K | $4.00 | +$2.00M | New position252.9K after | 2 lots |
| Nov 29, 2022 (view filing)4:36 PM ET | Nov 25 | 4 days | OrbiMed Advisors LLC and 2 others10% Owner | PPurchase | +762.4K | $5.25 | +$4.00M | +16.7%5.33M after | |
| Oct 11, 2022 (view filing)7:10 PM ET | Oct 6-10 | 5 days | Rocklage Scott M and 7 others10% Owner | SSale | −600.0K | $4.15 | −$2.49M | −59.4%410.3K after | 6 lots |
| Sep 8, 2022 (view filing)7:58 PM ET | Sep 6-7 | 2 days | Rocklage Scott M and 7 others10% Owner | SSale | −226.6K | $4.84 | −$1.10M | −31.1%503.1K after | 6 lots |
| Apr 13, 2022 (view filing)4:51 PM ET | Apr 11 | 2 days | Rocklage Scott M and 7 others10% Owner | SSale | −270.0K | $5.00 | −$1.35M | −33.4%537.3K after | 3 lots |
| Dec 6, 2021 (view filing) | Dec 3 | 3 days | Khattar Jack A.Director | PPurchase | +5.00K | $3.91 | +$19.6K | New position5.00K after | |
| Dec 6, 2021 (view filing) | Dec 3 | 3 days | Tucker John HPresident and CEO | PPurchase | +10.0K | $3.96 | +$39.6K | +27.1%47.0K after |
Top 10 13F holders, Q3 2025
The largest institutional positions in scPharmaceuticals Inc. at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 6,059,528 | $34.4M | 0.82% | 00.0% | Unchanged |
| Rubric Capital Management LP | 5,101,886 | $28.9M | 0.39% | +499,909+10.9% | Added |
| Weiss Asset Management LP | 2,881,669 | $16.3M | 0.23% | +2,881,669 | New |
| BlackRock, Inc. | 2,380,477 | $13.5M | 0.00% | +169,161+7.6% | Added |
| Vanguard Group Inc | 2,176,970 | $12.3M | 0.00% | +341,321+18.6% | Added |
| Tudor Investment Corp Et Al | 2,150,000 | $12.2M | 0.08% | +2,150,000 | New |
| King Luther Capital Management Corp | 2,128,391 | $12.1M | 0.05% | −1,412,779−39.9% | Reduced |
| HSBC Holdings PLC | 1,900,042 | $10.8M | 0.01% | +1,900,042 | New |
| Morgan Stanley | 1,672,825 | $9.48M | 0.00% | −475,061−22.1% | Reduced |
| Glazer Capital, LLC | 1,381,691 | $7.83M | 0.26% | +1,381,691 | New |